MedPath

A prospective, randomized, double-blind, multicenter clinical study of Neiyifang in the treatment of congealing cold blood stasis of endometriosis

Not Applicable
Conditions
endometriosis
Registration Number
ITMCTR2200005646
Lead Sponsor
Shanghai Changhai Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

? All cases should meet EM clinical diagnostic criteria and TCM diagnostic criteria of congealing cold blood stasis syndrome;
? 18-40 years old;
? Menstrual cycle between 21 and 35 days, period of 3 to 7 days;
(4) VAS score =3, and pain must be continuous or recurrent for at least 6 months;
? Those who voluntarily participated in the experiment and signed the informed consent;
? Those who have not been treated with Western medicine or have been treated with western medicine but have stopped taking medicine for 3 months.

Exclusion Criteria

1) patients with adenomyosis;
2) Patients with serious diseases such as cardiovascular, cerebrovascular, liver, kidney, diabetes and tumor;
3) Mental illness and long-term alcohol or drug use affect cognition;
4) Patients with chronic pelvic pain caused by anxiety and depression (depression scale and anxiety scale =50 points). (Less than 50 on the SELF-rated Anxiety scale/Self-rated Depression scale was considered normal; A score of 50-60 was mild anxiety; A score of 61 to 70 indicates moderate anxiety, while a score of 70 or more indicates severe anxiety.)
5) Long-term use of painkillers or overuse of painkillers (more than 10 days in a month);
6) Suspected or confirmed history of smoking, alcohol and drug abuse;
7) Women who have positive pregnancy test, are pregnant or breast-feeding, or plan to have a pregnancy;
8) allergic constitution and known allergic to the composition of the drug;
9) Participants in other clinical trials or participants in clinical trials within 3 months prior to screening;
10) Patients with coagulation dysfunction and previous thrombotic diseases;
11) Those who are considered unsuitable for the clinical trial by the investigator.

Study & Design

Study Type
Treatment study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
remission rate of EAPP;
Secondary Outcome Measures
NameTimeMethod
CA125;TCM syndrome score;COX-Menstrual symptom score;VAS, DYS, NMPP of EAPP;EHP-5;
© Copyright 2025. All Rights Reserved by MedPath